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Hepatocyte growth factor-regulated tyrosine kinase
substrate (Hrs) is a mammalian homologue of yeast vac-
uolar protein sorting (Vps) protein Vps27p; however, the
role of Hrs in lysosomal trafficking is unclear. Here, we
report that Hrs interacts with sorting nexin 1 (SNX1), a
recently identified mammalian homologue of yeast
Vps5p that recognizes the lysosomal targeting code of
epidermal growth factor receptor (EGFR) and partici-
pates in lysosomal trafficking of the receptor. Biochem-
ical analyses demonstrate that Hrs and SNX1 are ubiq-
uitous proteins that exist in both cytosolic and
membrane-associated pools, and that the association of
Hrs and SNX occurs on cellular membranes but not in
the cytosol. Furthermore, endogenous SNX1 and Hrs
form a ;550-kDa complex that excludes EGFR. Immuno-
fluorescence and subcellular fractionation studies show
that Hrs and SNX1 colocalize on early endosomes. By
using deletion analysis, we have mapped the binding
domains of Hrs and SNX1 that mediate their association.
Overexpression of Hrs or its SNX1-binding domain in-
hibits ligand-induced degradation of EGFR, but does
not affect either constitutive or ligand-induced recep-
tor-mediated endocytosis. These results suggest that
Hrs may regulate lysosomal trafficking through its in-
teraction with SNX1.
Vesicular trafficking, the process by which a transport vesi-
cle buds from a donor membrane and fuses with its target, is
fundamental to the function of eukaryotic cells. For example, it
is becoming increasingly clear that vesicular trafficking of li-
gand-activated receptor tyrosine kinases such as epidermal
growth factor receptor (EGFR)1 plays a critical role in control-
ling diversity, intensity, and duration of tyrosine kinase sig-
naling (1, 2). Binding of EGF triggers the dimerization of EGFR
and the activation of the tyrosine kinase at the cytoplasmic
domain of the receptor, which then activates downstream sig-
nal transduction pathways (3). After ligand binding, the ligand-
receptor complexes are recruited to clathrin-coated pits and
internalized. Following endocytosis, the ligand-receptor com-
plexes are transported to early endosomes, where a sorting
decision must be made between recycling back to the cell sur-
face or delivery to lysosomes for degradation. The internalized
EGFzEGFR complexes are primarily transported to lysosomes,
and their degradation represents a major mechanism for at-
tenuating EGF signaling (4). Moreover, accumulating evidence
indicates that the internalized EGFzEGFR continues to bind
and phosphorylate downstream signaling proteins in pre-deg-
radative intracellular compartments, leading to activation of
signaling pathways that are distinct from those originated at
the cell surface (2, 5). To ensure proper temporal and spatial
signaling, the endocytic and lysosomal trafficking of EGF re-
ceptors is tightly regulated. Whereas the major events in en-
docytosis are fairly well understood, the molecular mechanisms
underlying lysosomal trafficking of these receptors remain
poorly characterized.
Hepatocyte growth factor-regulated tyrosine kinase sub-
strate (Hrs) was identified originally as a phosphoprotein
whose tyrosine phosphorylation is induced upon stimulation by
hepatocyte growth factor (6). Subsequent studies demonstrate
that the tyrosine phosphorylation of Hrs is also induced by a
variety of other growth factors and cytokines, including epider-
mal growth factor (EGF), platelet-derived growth factor
(PDGF), interleukin 2, and granulocyte-macrophage colony-
stimulating factor (6, 7). Hrs exists in cytosolic and membrane-
associated forms, and appears to function in both signaling and
vesicular trafficking (6–9). Hrs is thought to function in cell
growth signaling by cytokines via its interaction with signal
transducing adaptor molecule (STAM) (7). Recently, it was
reported that Hrs also interacts with Hbp/STAM2, an STAM
isoform involved in cytokine signaling and degradation of
PDGF receptors (10, 11). In addition, our previous work has
demonstrated that Hrs regulates the exocytotic fusion process
via its interaction with SNAP-25, an essential component of the
membrane fusion machinery (9). Hrs shares 20% sequence
identity and similar domain structure with Vps27p, a yeast
protein that is required for trafficking of proteins from a pre-
vacuolar/endosomal compartment to Golgi and vacuole, the
yeast equivalent of the lysosome (8, 9, 12). Targeted disruption
of Hrs gene in mice leads to abnormally enlarged early endo-
somes that are reminiscent of exaggerated “class E” compart-
ment in yeast vps27 mutant, suggesting that Hrs may have an
analogous function in vesicular trafficking through mamma-
lian endosomes (8, 13). However, it has yet to be demonstrated
whether Hrs actually acts in endosome-to-Golgi and endosome-
to-lysosome trafficking in mammalian cells.
To understand the action of Hrs in vesicular trafficking and
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signaling, we performed a search for proteins that interact with
Hrs using a yeast two-hybrid screen. We report here the isola-
tion and characterization of a Hrs-interacting protein that is
the rat counterpart of the human sorting nexin 1 (SNX1) (14).
SNX1 was first identified as a protein that interacts with the
lysosomal targeting signal-containing cytoplasmic region of
EGFR (14). Overexpression of SNX1 accelerates degradation of
EGFR, suggesting a role for SNX1 in endosome-to-lysosome
trafficking (14). It remains controversial as to whether SNX1
interacts only with EGFR (14) or additionally with multiple
types of other cell surface receptors, including the receptors for
PDGF, insulin, leptin, and transferrin (15). Interestingly,
SNX1 is homologous to Vps5p, a yeast protein that is required
for endosome-to-Golgi trafficking (16–18). Recent evidence in-
dicates that Vps5p is a molecular component of a multimeric
membrane-associated protein complex termed the retromer
complex, which serves as a novel membrane coat acting in the
formation of vesicles for endosome-to-Golgi trafficking (18). It
thus likely that SNX1 may function in a similar manner in
mammalian cells, acting as a key component of the lysosomal
sorting machinery by incorporating cargo proteins into a ret-
romer-like membrane coat.
In the present study, we demonstrate that Hrs interacts with
SNX1 both in vitro and in vivo. We define the structural re-
quirement for this novel interaction and show that the Hrs-
binding site of SNX1 overlaps with its EGFR-binding site. In
addition, gel filtration analysis and coimmunoprecipitation
studies reveal that SNX1 and Hrs form a ;550-kDa complex
that excludes EGFR. We characterize the expression pattern
and subcellular localization of SNX1 and show that it colocal-
izes with Hrs on early endosomes. Furthermore, we show that
Hrs and SNX1 are involved in the regulation of the ligand-
induced degradation of EGF receptors, but not in the internal-
ization of these receptors. Our data suggest that Hrs may
regulate lysosomal sorting and trafficking pathways via its
interaction with SNX1.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screens and Interaction Assays—A bait plasmid,
pPC97-Hrs, was constructed by subcloning the entire open reading
frame of rat Hrs (9) into the pPC97 vector (19, 20). For the two-hybrid
screen, the yeast strain CG-1945 (CLONTECH) was transformed se-
quentially with pPC97-Hrs and a rat hippocampal/cortical two-hybrid
cDNA library (20). Positive clones were selected on 3-aminotriazole-
containing medium lacking leucine, tryptophan, and histidine, and
confirmed by a filter assay for b-galactosidase activity (21). Prey plas-
mids from positive clones were rescued and re-transformed into fresh
yeast cells with the Hrs bait or various control baits to confirm the
specificity of the interaction. For analysis of Hrs-SNX1 interaction,
deletion constructs of Hrs and SNX1 were made by polymerase chain
reaction and were subcloned into the pPC97 vector. The interactions
between these Hrs and SNX1 fragments were tested in the yeast two-
hybrid assay by using HIS3 and b-galactosidase as the reporter genes.
Quantitative b-galactosidase assay was performed on the yeast extracts
by using the substrate chlorophenol red b-D-galactopyranoside as de-
scribed previously (21, 22).
cDNA Cloning—For cloning of the full-length rat SNX1, a rat hip-
pocampal cDNA library in lZAPII (Stratagene) was screened using a
partial SNX1 cDNA probe from the yeast two-hybrid prey clone, accord-
ing to standard procedures (23). The cDNA inserts from positive SNX1
clones were sequenced multiple times on both strands, using an Applied
Biosystems 373A DNA sequencer.
Antibodies—An anti-SNX1 antibody was raised in chicken against
the COOH-terminal peptide of rat SNX1, CKYWEAFLPEARAIS. The
NH2-terminal cysteine residue was added for the coupling purposes.
The antibody was affinity-purified using the immunogen peptide cou-
pled to a SulfoLink column (Pierce). Other antibodies that were used in
this study are: anti-Hrs (9); anti-EGFR (1005 and 528, Santa Cruz
Biotechnology, Inc.), anti-SNAP-25 (SMI 81, Sternberger Monoclonals,
Inc.); anti-Rab5, anti-Rab11, and anti-EEA1 (Transduction Laborato-
ries); anti-HA (3F10, Roche Molecular Biochemicals); anti-actin (C4,
Roche Molecular Biochemicals); and secondary antibodies coupled with
Texas Red (Jackson ImmunoResearch Laboratories). The anti-LAMP1
(H4A3) and anti-LAMP2 (H4B4) antibodies were obtained from the
Developmental Studies Hybridoma Bank maintained by the University
of Iowa (Iowa City, IA).
Western Blot Analyses—Rat tissues were homogenized in 1% SDS
and subjected to SDS-PAGE. The proteins were transferred onto nitro-
cellulose membranes, and probed with the anti-SNX1 and other anti-
bodies. Antibody binding was detected by using the enhanced chemilu-
minescence system (Amersham Pharmacia Biotech).
Production of Recombinant Proteins—The full-length rat SNX1 was
subcloned into the prokaryotic expression vectors pET32c (Novagen) to
obtain the construct pET32-SNX1. This plasmid encodes a fusion pro-
tein, S-tag-SNX1, which consists of (from amino to carboxyl terminus)
the 109-amino acid thioredoxin protein, a hexahistidine tag, and a
15-amino acid S-tag peptide fused in frame with the SNX1 protein. For
the production of glutathione S-transferase (GST)-Hrs fusion proteins,
rat Hrs (residues 225–776) was subcloned into the vector pGEX-5X-2
(Amersham Pharmacia Biotech). Fusion proteins were expressed in
bacteria, and purified as described previously (21).
In Vitro Binding Assays—GST-Hrs fusion protein or GST control was
immobilized on glutathione-agarose beads, and incubated with S-tag-
SNX1 fusion protein for 3 h at 4 °C under gentle rocking in 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, and 0.1% Triton X-100. After extensive
washes with the same solution, bound proteins were eluted by boiling in
Laemmli sample buffer, subjected to SDS-PAGE, and immunoblotting
using horseradish peroxidase-conjugated S-protein (Novagen), and vi-
sualized by enhanced chemiluminescence (ECL, Amersham Pharmacia
Biotech). For detection of the interaction of Hrs with endogenous SNX1,
GST-Hrs fusion proteins immobilized on glutathione-agarose beads
were incubated with rat brain homogenates for 2 h at 4 °C as described
(21). Bound proteins were analyzed by SDS-PAGE and immunoblotting.
Expression Constructs and Transfections—Conventional molecular
biological techniques (23) were used to generate the following expres-
sion constructs: pcDNA3.1-SNX1 and pcDNA3.1-Hrs, which direct the
expression of full-length SNX1 and Hrs, respectively; pCHA-SNX1,
pCHA-Hrs, and pCHA-Hrs225–776, which direct the expression of NH2-
terminal HA epitope-tagged, full-length SNX1, full-length Hrs, and a
Hrs fragment (residues 225–776), respectively; and pEGFP-SNX1,
pEGFP-Hrs, and pEGFP-Hrs225–776, which direct the expression of
NH2-terminal GFP-tagged, full-length SNX1, full-length Hrs, and a Hrs
fragment (residues 225–776), respectively. Transfections of HEK293
and HeLa cells were performed using LipofectAMINE (Life Technolo-
gies, Inc.) according to the manufacturer’s instructions.
Immunoprecipitation—Extracts were prepared from HeLa cells tran-
siently transfected with pAlterMAX-EGFR alone (0.1 mg) or in combi-
nation with pCHA-SNX1 or pCHA-Hrs (1 mg), and immunoprecipitation
were performed as described previously (24), using anti-HA antibody
(3F10), anti-EGFR antibody (528), or corresponding control IgG. For
coimmunoprecipitation of SNX1 and Hrs in cellular fractions, HA-
SNX1-transfected cells were homogenized in buffer A (50 mM Tris-HCl,
pH 7.6, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin, and 10 mg/ml benzamide) and centrifuged at 16,000 3 g for
15 min. After removal of the supernatant (cytosol) fraction, the partic-
ulate fraction was resuspended with buffer A containing 1% Nonidet
P-40 and incubated at 4 °C for 30 min to solubilize membrane-bound
proteins. The cytosol and membrane fractions were centrifuged at
100,000 3 g for 20 min at 4 °C, and the supernatants were incubated
with rat monoclonal anti-HA antibody (3F10) or control rat IgG for 1 h
at 4 °C. The immunocomplexes were recovered by incubation with pro-
tein G-Sepharose beads (Sigma) for 1 h at 4 °C. After extensive washes
with the same solution, the immunocomplexes were dissociated by
boiling in the Laemmli sample buffer, and analyzed by SDS-PAGE and
immunoblotting.
Membrane Association Analyses—Separation of PC12 cells into cy-
tosol fraction (100,000 3 g supernatant) and membrane particulate
fraction (100,000 3 g pellet) were performed as described previously
(21). The membrane fractions were subjected to extraction studies as
described (21), using 1.5 M NaCl or 4 M urea.
Subcellular Fractionation—HeLa cells were treated with 100 ng/ml
EGF for 10 min at 37 °C and then washed twice with PBS at 4 °C. Cells
were gently scraped from culture plates and collected by centrifugation.
They were then homogenized in 1 ml of ICT (78 mM KCl, 4 mM MgCl2,
8.37 mM CaCl2, 10 mM EGTA, 50 mM HEPES/KOH, pH 7.0) plus 250 mM
sucrose (25), and centrifuged at 1,000 3 g for 5 min. The supernatant
was placed on a 5–20% linear Optiprep (Nycomed) gradient formed in
ICT, and centrifuged at 4 °C for 20 h at 125,000 3 g in a SW40 rotor
(Beckman). Following centrifugation, the gradient was harvested into
300-ml fractions using an Auto Densi-Flow gradient harvester
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(Labconco).
Size Exclusion Chromatography—HeLa cells were treated with 100
ng/ml EGF for 10 min at 37 °C, and then lysed for 30 min at 4 °C in a
lysis buffer (50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 0.1% Triton X-100,
1% Nonidet P-40) containing protease inhibitors (1 mM phenylmethyl-
sulfonyl fluoride and 10 mg/ml each of leupeptin, aprotinin, benzami-
dine, and pepstatin). After centrifugation at 16,000 3 g for 15 min, the
supernatant was concentrated into 7.8 mg/ml protein in the elution
buffer (40 mM HEPES, pH 7.8, 2 mM EDTA, 10% glycerol, 50 mM KCl,
1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride). The extract
(500 ml) was loaded on a Superose 6 HR 10/30 column and fractionated
by size-exclusion chromatography, using a ÄKTAdesign advanced chro-
matography system (Amersham Pharmacia Biotech). The column was
eluted using a flow rate of 0.5 ml/min, and 0.25-ml fractions were
collected. The column was calibrated with protein standards (Sigma),
including blue dextran, thyroglobulin, apoferritin, b-amylase, alcohol
dehydrogenase, albumin, and carbonic anhydrase.
Immunofluorescence Microscopy—HeLa cells were fixed with 4%
paraformaldehyde and processed for indirect immunofluorescence mi-
croscopy as described previously (21). The distributions of GFP-Hrs and
GFP-SNX1 were compared with the distribution of marker proteins
using a Leica TCS-NT confocal microscope with fluorescein isothiocya-
nate and Texas Red filters. To avoid bleed-through, images were col-
lected by sequential scanning for fluorescein isothiocyanate or Texas
Red while turning off the other laser. The images were then processed
using Adobe Photoshop 5.0 (Adobe Systems, Inc.).
Endocytosis Assays—For measurement of transferrin endocytosis,
transfected HeLa cells were incubated in serum-free medium for 1 h,
followed by addition of 100 mg/ml Texas Red-conjugated transferrin
(Molecular Probes) and incubation at 37 °C for 30 min in the absence or
presence of 100 ng/ml EGF. The cells were then were washed with
phosphate-buffered saline, fixed with 4% paraformaldehyde, and pro-
cessed for indirect immunofluorescence microscopy as described above.
For measurement of EGFR endocytosis, HeLa cells were incubated in
serum-free medium for 1 h and then incubated in the absence or
presence of 100 ng/ml EGF for 10 min at 37 °C. After washing with
phosphate-buffered saline, the cells were fixed and stained with anti-
EGFR antibodies followed by Texas Red-conjugated secondary antibod-
ies (21).
Assays for Degradation of EGFR—Cultures of HeLa cells in 10-cm
dishes were transiently transfected with 0.10 mg of pAlterMAX-EGFR
(24) in combination with 2 mg of pCHA vector, pCHA-Hrs, pCHA-
Hrs225–776, or pCHA-SNX1. After 24 h, cells were incubated in serum-
free medium for 1 h and then incubated in the absence or presence of
100 ng/ml EGF for 45 min at 37 °C. Cell lysates were prepared as
described (24). Equal amount (600 mg) of protein from each lysate was
immunoprecipitated using anti-EGFR antibody 528. The immunopre-
cipitates were subjected to immunoblotting with anti-EGFR antibody
1005 and enhanced chemiluminescence (ECL) detection. Signals were
digitized using MTI CCD-72S camera (DAGE-MTI, Inc.), and the in-
tensity of the EGFR band (180 kDa) was quantitated using MCID M4
software (Imaging Research Inc.).
RESULTS
Identification of Rat SNX1 as a Hrs-binding protein in Yeast
Two-hybrid Screens—To identify proteins that interact with
Hrs, we screened a rat hippocampal/cortical cDNA library us-
ing a full-length Hrs as bait in the yeast two-hybrid selection.
Positive clones were rescued, and confirmed by re-transforma-
tion experiments. Of the 22 positive clones sequenced, 4 clones
encoded STAM, a signal-transducing adaptor molecule that is
known to interact with Hrs (7). Three independent overlapping
clones encoded portions of a protein that is the rat homologue
of the human sorting nexin 1 (Fig. 1A). The specificity of the
interaction between Hrs and SNX1 was confirmed by yeast
two-hybrid analysis demonstrating that SNX1 only interacts
with Hrs, but not with a coiled-coil domain-containing protein
SNAP-25 or the proline-rich cytoplasmic region of synaptophy-
sin (data not shown).
By screening a rat hippocampal lZAP cDNA library, we
isolated two full-length and four partial cDNA clones of rat
SNX1. The full-length rat SNX1 cDNA (accession no.
AF218916) contains an open reading frame encoding a 522-
amino acid protein (Fig. 1B) that is 95% identical to human
SNX1 (14, 15). Sequence analysis demonstrated that rat SNX1
is hydrophilic with a theoretical isoelectric point (pI) of 5.15
and a high percentage (30%) of charged amino acids distributed
over the entire length. Like human sorting nexins, rat SNX1
contains a Phox homology (PX) domain (15, 26). The PX do-
main, whose function is as yet unknown, is an evolutionarily
conserved sequence that is present in a number of proteins
with diverse function, including proteins involved in vesicular
trafficking (15–17, 26–29). By using the algorithm of Lupas et
al. (30), we identified three regions with high probability (p 5
0.94, 0.98, and 1.00, respectively) of forming a coiled-coil struc-
ture. In addition, rat SNX1 contains three putative SH3 do-
main-binding (PXXP) motifs (31). Thus, SNX1 could potentially
interact with multiple proteins or be involved in the formation
of multi-protein complexes via coiled-coil interactions, associa-
tions of its proline-rich motifs with the SH3 domain-containing
proteins, and/or other types of protein-protein interactions
through its PX domain.
Tissue Distribution and Membrane Association of SNX1—To
FIG. 1. Structure of rat sorting
nexin 1. A, domain structure of rat
SNX1. The following domains are indi-
cated: PX domain (residues 161–272); H1,
H2, and H3, predicted coiled-coil domain
1 (residues 309–342), coiled-coil domain 2
(residues 356–388), and coiled-coil do-
main 3 (residues 440–476). The locations
of the Hrs-interacting SNX1 clones iso-
lated from the yeast two-hybrid screens
are indicated below the domain structure.
B, sequence of rat SNX1. The nucleotide
sequence of rat SNX1 (not shown) has
been deposited in GenBanky with the ac-
cession number AF218916. The deduced
amino acid sequence of rat SNX1 is shown
in single-letter code and numbered on the
left. In-frame stop codon is denoted with
an asterisk. Indicated are the phox homol-
ogy domain (dashed underline), the pred-
icated coiled-coil domains (underline),
and potential SH3 domain interaction
motifs (boxes).
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analyze SNX1 expression at protein level and biochemically
characterize its association with Hrs, we raised a chicken poly-
clonal antibody against the COOH-terminal 14-amino acid pep-
tide of rat SNX1. To characterize this antibody, HEK293 cells
were transfected with an expression construct pCHA-SNX1,
which directed the expression of a HA epitope-tagged, full-
length SNX1 protein (HA-SNX1) (Fig. 2A). Immunoprecipita-
tion of HA-SNX1 with an anti-HA antibody followed by immu-
noblotting with the anti-SNX1 antibody demonstrated that the
antibody is able to recognize the recombinant SNX1 protein
(Fig. 2A). The specificity of the anti-SNX1 antibody was con-
firmed by the following experiments. 1) The preimmune
chicken IgY did not react with the recombinant or endogenous
SNX1 proteins (data not shown). 2) Pre-absorption of the anti-
SNX1 antibody with recombinant SNX1 protein or the peptide
immunogen completely eliminated its immunoreactivity to
both recombinant and endogenous SNX1 protein (data not
shown).
Although the tissue distribution of SNX1 mRNA expression
has previously been determined (15), the distribution of SNX1
protein expression has not yet been reported. To analyze the
tissue distribution of SNX1 at protein level, affinity-purified
anti-SNX1 antibodies were used on Western blots of various rat
tissues. A doublet of protein bands with an apparent molecular
masses of 66 and 61 kDa was detected (Fig. 2B). The size of the
upper band agrees well with that of the endogenous SNX1
protein detected in murine NIH 3T3 and human HeLa cells
(14). The lower band is likely to be the alternatively spliced
isoform SNX1A, which has an NH2-terminal internal 65-amino
acid deletion compared with SNX1 (15). As shown in Fig. 2B,
SNX1 is abundantly expressed in pancreas, spleen, kidney,
intestine, and lung, and moderately expressed in brain, liver,
and ovary. Longer exposure of the same blot demonstrated that
SNX1 is also present at low level in heart and skeletal muscle
(data not shown). The additional immunoreactive bands of low
molecular weights observed in pancreas and intestine are
likely to be the degradation products of SNX1/1A since the
relative intensity of these bands as compared with the
SNX1/1A bands varied from preparation to preparation.
To examine the intracellular distribution of endogenous
SNX1, postnuclear supernatant of PC12 cells was separated
into cytosol and membrane particulate fraction, and then sub-
jected to Western blot analysis with the anti-SNX1 antibody
(Fig. 2C). SNX1 immunoreactivity was detected in both cytosol
and membrane particulate fraction, although the relative
amount of SNX1 in the cytosol fraction was severalfold more
than that in the particulate fraction. To investigate the nature
of SNX1 association with membranes, the membrane particu-
late fraction was extracted with 1.5 M NaCl or 4 M urea (Fig.
2C). Unlike the integral membrane protein EGFR, which was
resistant to extraction by high salt and urea, SNX1 was ex-
tracted by these treatments, suggesting that SNX1 is periph-
erally associated with membranes.
Hrs and SNX1 Associate in Vitro—To obtain independent
evidence for the interaction between Hrs and SNX1, GST-Hrs
fusion protein or GST control was immobilized on glutathione-
agarose beads, and incubated with S-tag-SNX1 fusion protein.
Proteins that bound to the GST-Hrs or GST control were de-
tected with the horseradish peroxidase-conjugated S protein
against the S-tag (Fig. 3A). The results demonstrate that S-tag-
SNX1 bound to GST-Hrs, but not to the GST control, indicating
FIG. 2. Characterization of expression and membrane associ-
ation of SNX1. A, specificity of the anti-SNX1 antibody. HEK293 cells
were transfected with pCHA-SNX1 or pCHA vector control. Cell lysates
prepared from the transfected cells were immunoprecipitated (IP) with
an anti-HA antibody. The precipitates were then analyzed by immuno-
blotting (IB) with anti-HA antibody and anti-SNX1 antibody. B, West-
ern blot analysis of SNX1 expression in rat tissues. Equal amounts of
homogenates (30 mg of protein/lane) from indicated rat tissues were
analyzed by immunoblotting using the anti-SNIP antibody. Sk., Skele-
tal. C, nature of SNX1 association with cellular membranes. Post-
nuclear supernatant (T) from PC12 cells was separated into cytosol (C)
and membrane (M) fractions. The membranes were extracted with 1.5
M NaCl or 4 M urea, and then separated into soluble (S) and pellet (P)
fractions. Aliquots representing an equal percentage of each fraction
were analyzed by SDS-PAGE and immunoblotting for SNX1 and EGFR.
FIG. 3. Biochemical characterization of the association of Hrs
with SNX1. A, recombinant Hrs and SNX1 associate in vitro. GST or
GST-Hrs fusion proteins were immobilized on glutathione-agarose
beads and then incubated with S-tag-SNX1 (Input). After extensive
washes, bound proteins were analyzed by SDS-PAGE and probing with
the horseradish peroxidase-conjugated S-protein that specifically binds
the S-tag. B, binding of endogenous SNX1 to immobilized GST-Hrs
fusion proteins. Rat brain homogenate (Input) was incubated with
immobilized GST control or GST-Hrs fusion proteins. Bound proteins
were analyzed by immunoblotting with the affinity-purified anti-SNX1
antibody. C, in vivo association of Hrs and SNX1. HEK293 cells trans-
fected with HA-tagged SNX1 and FLAG-tagged Hrs were separated
into cytosol and membrane fractions, and then subjected to immuno-
precipitation using a rat antibody against HA tag or control rat IgG.
The immunoprecipitates were then immunoblotted with antibodies
against Hrs and HA tag.
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that recombinant Hrs and SNX1 are capable of interacting
directly with each other. To determine whether recombinant
Hrs is able to bind endogenous SNX1, GST-Hrs fusion protein
immobilized on glutathione beads was used to affinity-purify
(“pull-down”) endogenous SNX1 from brain homogenates. As
shown in Fig. 3B, the GST-Hrs fusion protein was able to pull
down endogenous SNX1. In contrast, control GST protein was
unable to pull down SNX1. These results confirm the Hrs-
SNX1 interaction detected in the yeast two-hybrid system.
Association of Hrs and SNX1 Occurs on Cellular Membranes
but Not in Cytosol—Coimmunoprecipitation experiments were
performed to determine whether Hrs interacts with SNX1 in
vivo. Since both Hrs and SNX1 exist in a cytosolic pool and a
membrane-associated pool (Fig. 2C) (9), we were interested to
know whether the association of Hrs and SNX1 occurs in the
cytosol or on membranes. To examine these possibilities, HA-
SNX1-transfected HeLa cells were fractionated into the cytosol
and membrane fractions. These fractions were then subjected
to immunoprecipitation with a rat anti-HA antibody or control
rat IgG, and the immunoprecipitates were analyzed by West-
ern blot analysis using antibodies against Hrs and HA tag (Fig.
3C). The results demonstrate that Hrs and SNX1 coimmuno-
precipitate only in the membrane fraction, but not in the cy-
tosol fraction. Moreover, control IgG was unable to precipitate
either SNX1 or Hrs, confirming the specificity of the observed
Hrs-SNX1 association.
Identification of the Hrs-binding Domain in SNX1—The
three SNX1 clones isolated from yeast two-hybrid screens en-
code residues 123–522, 178–522, and 253–522 of rat SNX1
(Fig. 1A), indicating that the NH2-terminal 252 residues in-
cluding most of the PX domain of SNX1 is dispensable for the
association with Hrs. To further determine the specific region
in SNX1 that is responsible for binding Hrs, we made a series
of SNX1 deletion mutants that were expressed in yeast as
fusion proteins with the GAL4 DNA binding domain (Fig. 4A).
The interaction of these SNX1 deletion mutants with the full-
length Hrs was analyzed by the ability to grow on histidine-
deficient media and a b-galactosidase filter assay (data not
shown) as well as a quantitative b-galactosidase assay (Fig.
4A). The results demonstrated that the SNX1 COOH-terminal
region (residues 300–522) interacts strongly with Hrs, whereas
neither the PX domain (residues 158–282) nor COOH-terminal
fragments (residues 300–399 or residues 429–522) is able to
bind Hrs. These data suggest that multiple domains and/or a
complex folded structure of the SNX1 COOH-terminal region
(residues 300–522) are required for binding Hrs. The Hrs-
binding domain of SNX1 overlaps with its EGFR-binding site,
which has been mapped to the COOH-terminal 58 amino acids
(residues 465–522) of SNX1 (14).
Identification of the SNX1-binding Domain in Hrs—To fur-
ther understand the structural requirements that underlie the
interaction between Hrs and SNX1, we performed similar de-
letion analysis to map the specific region of Hrs involved in
binding SNX1 (Fig. 4B). Deletions of the VHS domain, FYVE
finger, and the COOH-terminal proline-rich domain had little
effect on the ability of Hrs to bind SNX1, indicating that these
domains are dispensable to the Hrs-SNX1 interaction. As
shown in Fig. 4B, only the fusion proteins that contain the
central region (residues 225–541) encompassing the two pre-
dicted coiled-coil domains H1 and H2 of Hrs were able to
interact with SNX1. Unlike the interaction of Hrs with STAM,
Hbp, or SNAP-25, which is mediated by the H2 domain (7, 8,
11), we found that the H2 domain (residues 443–541) by itself
is not sufficient to bind SNX1. Moreover, a Hrs fusion protein
FIG. 4. Identification of interacting
domains of Hrs and SNX1. A, mapping
of the Hrs-binding domain of SNX1. Ex-
pression plasmids encoding full-length
SNX1 and the indicated SNX1 deletion
mutants fused to the GAL4 DNA binding
domain were cotransformed into yeast
CG-1945 cells with pPC86-Hrs, a plasmid
encoding full-length Hrs fused to the
GAL4 activation domain. The interac-
tions of SNX1 deletion mutants with Hrs
were tested using yeast two-hybrid as-
says. The, b.-galactosidase activity of
each sample was determined using the
substrate chlorophenol red b-D-galactopy-
ranoside, normalized to its protein con-
tent, and expressed as a percentage of the
activity of full-length SNX1. B, mapping
of the SNX1-binding domain of Hrs. Ex-
pression plasmids encoding full-length
Hrs and the indicated Hrs deletion mu-
tants fused to the GAL4 activation do-
main were cotransformed into yeast CG-
1945 cells with pPC97-SNX1. Yeast two-
hybrid assays were performed as in A.
The b-galactosidase activity of each sam-
ple was expressed as a percentage of the
activity of full-length Hrs. Data are
shown as mean 6 S.D. of the results from
triplicate determinations.
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(residues 225–449) containing the H1 domain and the proline-
rich linker region was unable to bind SNX1. Taken together,
these data suggest that multiple domains and/or a complex
folded structure of the Hrs central region (residues 225–541)
are involved in binding SNX1.
Cofractionation of SNX1 with Hrs and with Early Endoso-
mal Markers on a Density Gradient—Since both Hrs and SNX1
exist in cytosolic and membrane-associated pools, we sought to
determine whether Hrs and SNX1 associate with the same
population of membranes by using subcellular fractionation.
Postnuclear supernatants were prepared from HeLa cells and
fractionated on a 5–20% linear Optiprep gradient using a well
established protocol (25). Fractions were collected and ana-
lyzed by SDS-PAGE and Western blot analysis (Fig. 5). As
expected, a portion of Hrs and SNX1 were detected as soluble
proteins in very low density regions (fractions 3–9). Further-
more, there is clear cofractionation between Hrs and SNX1 in
the denser regions (fractions 26–28), suggesting that the mem-
brane-bound pools of these two proteins associate with the
same population of membranes.
We next examined the organellar origin of the membrane
compartment to which Hrs and SNX1 are colocalized. Previous
studies using immunofluorescence staining and immunoelec-
tron microscopy demonstrate that Hrs is localized to the cyto-
plasmic surface of early endosomes (8). Based on these studies,
the population of membranes to which Hrs and SNX1 are
colocalized is likely to represent the early endosomes. To con-
firm this possibility, we determined the distributions of Rab5,
Rab11, and LAMP2 marker proteins in the same fractions of
the Optiprep gradient using Western blot analysis (Fig. 5).
Rab5, a marker for early endosomes (32), was detected in a
membrane-associated pool with a peak at fraction 27. In con-
trast, Rab11, a marker for recycling endosomes (33), exhibited
a membrane-associated peak around fraction 25. Consistent
with the results of Sheff et al. (25), we observed the presence of
a large fraction of Rab5 and Rab11 in very low-density regions
(fractions 4–7). Unlike Rab5 and Rab11 in the denser regions
(fractions 24–29), which could be quantitatively pelleted when
centrifuged at 165,000 3 g, both Rab proteins in the light
fractions did not pellet after the ultracentrifugation, indicating
that the low density Rab5 and Rab11 are soluble instead of
membrane-bound. LAMP2, a marker for late endosomes and
lysosomes (34), was localized to high density fractions (frac-
tions 32–34). Comparison of the distribution of Hrs and SNX1
with these markers suggests that Hrs and SNX1 primarily
associate with early endosomes, although we cannot exclude
the possibility that a small percentage of these proteins are
also localized to recycling endosomes.
Colocalization of Hrs and SNX1 on Early Endosomes by
Immunofluorescence Microscopy—To further confirm the colo-
calization of Hrs and SNX1 within the cell, full-length, amino-
terminally HA- or GFP-tagged Hrs and SNX1 were expressed
in HeLa cells, and their intracellular distribution was analyzed
by indirect immunofluorescence and confocal microscopy. The
tagged Hrs and SNX1, when expressed at low levels, exhibited
vesicular staining patterns (Fig. 6, A and B) which are indis-
tinguishable from those observed for nontagged Hrs and SNX1
when visualized using the antibodies against Hrs and SNX1
(data not shown). These staining data are consistent with the
results reported by Komada et al. (8) for Hrs and by Kurten et
al. (14) for SNX1. The SNX1-positive vesicular compartment
overlapped to a significant extent with Hrs, showing that at
least a subpopulation of SNX1 colocalizes with Hrs (Fig. 6,
compare A and B). Furthermore, recombinant Hrs, when ex-
pressed at high levels, caused the formation of enlarged vesic-
ular structures (Fig. 6D), which are believed to be exaggerated
early endosomes (8, 35). Although overexpression of recombi-
nant SNX1 alone does not lead to formation of enlarged vesic-
ular structures, SNX1 colocalized with Hrs to the exaggerated
vesicular structures resulted from high level Hrs expression
(Fig. 6, compare C and D). The colocalization of SNX1 with Hrs
is in agreement with the results of subcellular fractionation
studies (Fig. 5) and provides supporting evidence for an in vivo
association of Hrs with SNX1.
To investigate the identities of the vesicular structures la-
beled by Hrs and SNX1, we performed double immunofluores-
cence experiments to compare the distribution of these proteins
with early endosome antigen 1 (EEA1). EEA1, a core compo-
nent of early endosome docking and fusion machinery, has been
widely used as a marker for early endosomes (36, 37). Consist-
ent with previous studies (8) and our results of subcellular
fractionation (Fig. 5), a substantial overlap was observed be-
tween Hrs distribution and EEA1 immunoreactivity (compare
Fig. 7, A and B). Similarly, a majority of SNX1-positive vesic-
ular structures also contain EEA1 (compare Fig. 7, C and D).
Moreover, many of the vesicular structures labeled by Hrs and
SNX1 were stained by Rab5, another marker for early endo-
somes (Fig. 7, I and J; data not shown). However, no colocal-
ization was observed between the distribution of Hrs or SNX1
and that of LAMP1 and LAMP2, markers for late endosomes
and lysosomes (data not shown). Together, these results sug-
gest that Hrs and SNX1 primarily associate with early
endosomes.
To further confirm the early endosomal localization of Hrs
and SNX1, HeLa cells were stimulated for 10 min with EGF or
Texas Red-conjugated EGF, and the internalized EGFzEGFR
complexes were visualized by anti-EGFR antibodies (Fig. 7,
E–H) or by Texas Red-EGF labeling (data not shown). It is
known from previous studies using immunofluorescence and
immunoelectron microscopy that, under similar conditions, the
internalized EGFzEGFR complexes are almost exclusively lo-
calized to early endosomes (38, 39). As shown in Fig. 7, most of
the Hrs- and SNX1-positive structures contained internalized
EGFzEGFR complexes (Fig. 7, compare E and F, and G and H),
FIG. 5. Cofractionation of SNX1 with Hrs on an Optiprep gradient. Postnuclear supernatants were prepared from HeLa cells and
fractionated on a 5–20% linear Optiprep gradient as described under “Experimental Procedures.” The gradient was divided into 38 fractions, with
fraction 1 corresponding to the top of the gradient. Equal volumes of each fraction were analyzed by SDS-PAGE, followed by immunoblotting for
Hrs, SNX1, Rab5, Rab11, and LAMP2.
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providing further evidence for the early endosomal localization
of Hrs and SNX1. To examine possible association of Hrs and
SNX1 with recycling endosomes, HeLa cells were treated with
Texas Red-conjugated transferrin for 30 min. It is well estab-
lished that the internalized transferrin-receptor complexes ac-
cumulate in recycling endosomes, which are often concentrated
at the microtubule organizing center (40) (Fig. 7L). The punc-
tate staining pattern of SNX1 (Fig. 7K) or of Hrs (data not
shown) exhibited limited overlap with the distribution of inter-
nalized transferrin (Fig. 7L), suggesting that most of Hrs and
SNX1 does not associate with recycling endosomes. These data,
together with the results of subcellular fractionation (Fig. 5),
provide strong evidence for the colocalization of Hrs and SNX1
on early endosomes.
Hrs and SNX1 Coexist in a Large Protein Complex Within the
Cell—To further characterize the in vivo association of Hrs and
SNX1, we performed gel filtration analysis to assess the rela-
tive sizes of SNX1 and Hrs and their associated complexes in
HeLa cells. As shown in Fig. 8, fractionation of HeLa cell
extracts by size-exclusion chromatography on a Superose 6
high resolution column reveals that SNX1 exists in two distinct
protein complexes that eluted from the column with apparent
molecular masses of ;260 and ;550 kDa. In addition, a sig-
nificant portion of SNX1 eluted in the void volume fractions. No
SNX1 immunoreactivity was detected in the fractions corre-
sponding to the size of monomeric form of SNX1 (predicted
molecular mass of 59 kDa and apparent molecular mass of 66
kDa on SDS-PAGE), suggesting that SNX1 does not exist as
monomers in vivo. The ;260-kDa complex may represent a
SNX1 tetramer or a heteromeric complex of SNX1 with other
sorting nexin isoforms. Consistent with this possibility, HA-
tagged SNX2 has been shown to interact with itself and with
SNX1, SNX1A, and SNX4 (15). Similarly, it appears that Hrs
does not exist in the monomeric form (predicted molecular
mass of 86 kDa and apparent molecular mass of 110 kDa on
SDS-PAGE). The lowest apparent molecular weight of Hrs
detected by the size-exclusion chromatography is ;185 kDa,
which may correspond to a Hrs dimer or a heteromer of Hrs
with another protein such as STAM (7) or STAM2/Hbp (10, 11).
In contrast, monomeric form of EGFR was detected in the
fractions corresponding to its expected size.
The ;550-kDa SNX1-containing complex seems to also in-
clude Hrs, as suggested by the coelution of Hrs with SNX1 in
the same fractions (fractions 44–50). EGFR did not coelute
with SNX1 and Hrs in these fractions, suggesting that EGFR is
not part of the ;550-kDa complex. The size of ;550-kDa com-
plex is significantly larger than a simple heterodimer of
HrszSNX1, which has a combined molecular mass of ;175 kDa,
suggesting that the ;550-kDa complex contains either multi-
ple subunits of SNX1 and Hrs, or additional proteins such as
mammalian homologue of Vps17p (18).
As shown in Fig. 8, SNX1, Hrs, and EGFR coeluted in the
void volume of the Superose 6 column. This is reminiscent of
the coelution of yeast retromer components (Vps5p, Vps29p,
and Vps35p) in the void volume, which is thought to represent
a very large (.1000 kDa) complex (18). Thus, one possible
explanation of the data is that SNX1, Hrs, and EGFR may be
components of an analogous high molecular weight complex in
mammalian cells. Alternatively, the coelution of SNX1, Hrs,
and EGFR in the void volume could be the result of nonspecific
aggregation. The latter possibility seems to be more likely since
no heterotrimeric HrszSNX1zEGFR complex could be detected
in the coimmunoprecipitation experiments as shown in Fig. 9.
To further investigate the nature of Hrs- and SNX1-contain-
ing complexes, we performed coimmunoprecipitation experi-
ments using antibodies against EGFR, HA-Hrs, and HA-SNX1
(Fig. 9). Immunoprecipitation of HA-Hrs with an anti-HA an-
tibody was able to bring down endogenous SNX1 (Fig. 9, lane
3), further confirming the presence of a HrszSNX1 complex in
vivo. However, EGFR did not coprecipitate with HA-Hrs and
SNX1 (Fig. 9, lane 3), indicating that Hrs, SNX1, and EGFR do
not coexist in a single complex. These results are consistent
with the gel filtration data (Fig. 8) showing the presence of a
;550-kDa complex that contains Hrs and SNX1 but excludes
EGFR. Immunoprecipitation of EGFR with an anti-EGFR an-
tibody resulted in the coprecipitation of SNX1 but not Hrs (Fig.
9, lane 5), providing further evidence for the presence of the
SNX1zEGFR complex but not the HrszSNX1zEGFR complex in
vivo. As expected, immunoprecipitation of HA-SNX1 with an
anti-HA antibody was able to bring down both Hrs and EGFR
(Fig. 9, lane 1) due to the ability of the antibody to precipitate
both SNX1zHrs and SNX1zEGFR complexes. Together, these
coimmunoprecipitation data demonstrate that there are two
mutually exclusive complexes containing SNX1, one with Hrs
and one with EGFR. This is in agreement with the results of
deletion analysis (Fig. 4A) indicating that the Hrs-binding site
of SNX1 overlaps with its EGFR-binding site (14). It is inter-
esting to note that, although the SNX1zEGFR complex was first
reported by Kurten et al. (14), and subsequently confirmed by
Haft et al. (15) and this study, no such complex could be
detected in the gel filtration analysis (Fig. 8). Thus, the relative
abundance of the SNX1zEGFR complex seems to be very low
compared with the abundance of the SNX1zHrs complex in
HeLa cells.
Hrs and SNX1 Are Involved in Degradation but Not in In-
ternalization of EGFR—Since SNX1 has been shown to accel-
erate down-regulation of EGFR (14), the association and colo-
calization of Hrs with SNX1 raise the possibility that Hrs may
also have a role in the down-regulation of EGFR. To test this
possibility, we used a well established assay (14, 24, 41) to
evaluate the effect of overexpression of Hrs on the down-regu-
FIG. 6. Comparison of the intracellular distribution of SNX1
with Hrs by confocal fluorescence microscopy. HeLa cells were
transiently cotransfected with pEGFP-Hrs and pCHA-SNX1 (A and B)
or pEGFP-SNX1 and pCHA-Hrs (C and D). The distributions of GFP-
Hrs (A) and GFP-SNX1 (C) were directly visualized by the green fluo-
rescence emitted by the GFP. The same cells were stained with primary
antibodies against HA tag (B and D), followed by detection with sec-
ondary antibodies conjugated to Texas Red. The arrows indicate vesic-
ular structure clearly visible in both panels (colocalized), whereas the
arrowhead marks the vesicular structure visible in one panel but not
the other (not colocalized). Scale bar 5 10 mm.
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lation of EGFR (Fig. 10). In agreement with previous reports
(14, 41), we observed that, in vector-transfected control cells,
stimulation with EGF for 45 min led to a large decrease in the
number of mature EGFR. The EGF-induced down-regulation of
EGFR was significantly enhanced in cells overexpressing
SNX1, which is consistent with the results of Kurten et al. (14).
In contrast, overexpression of Hrs resulted in a significant
reduction in the EGF-induced down-regulation of EGFR. Sim-
ilar extent of reduction in the down-regulation of EGFR was
also observed in cells expressing a Hrs fragment (amino acids
225–776) containing the SNX1-interacting domain. These re-
sults suggest that Hrs is involved in the ligand-induced down-
regulation of EGFR, perhaps via its interaction with SNX1.
To determine whether the effect of overexpressing SNX1 and
Hrs on the down-regulation of EGFR is due to a change in the
internalization of EGFR, HeLa cells overexpressing SNX1 or
Hrs were tested for their capacity to internalize EGFzEGFR
complexes in the presence of EGF or Texas Red-conjugated
EGF. We found that, compared with untransfected cells, cells
overexpressing SNX1, Hrs, or Hrs225–776 internalized similar
amounts of EGFR and Texas Red-conjugated EGF (Fig. 7 (E–H)
and data not shown), indicating that overexpression of these
proteins has little effect on ligand-induced endocytosis/inter-
nalization of EGFR. Furthermore, no difference in the amount
of internalized transferrin was observed between cells overex-
pressing SNX1, Hrs, or Hrs225–776 and untransfected cells (Fig.
7L, and data not shown), suggesting that Hrs and SNX1 are not
involved in constitutive receptor-mediated endocytosis. Taken
together, these data suggest that SNX1 and Hrs alter the
down-regulation of EGFR by affecting lysosome trafficking of
the receptor for degradation.
FIG. 7. Comparison of the distribu-
tion of Hrs and SNX1 with markers
for early endosomes and recycling
endosomes. HeLa cells were transiently
transfected with either pEGFP-Hrs (A, B,
E, and F) or pEGFP-SNX1 (C, D, and
G–L). Transfected cells were identified by
the green fluorescence emitted by the
GFP (A, C, E, G, I, and K). Some of the
cells were treated at 37 °C with either
EGF for 10 min (E–H) or Texas Red-con-
jugated transferrin for 30 min (K and L).
Internalized transferrin was visualized
by the red fluorescence emitted by the
Texas Red (L). Cells were stained with
primary antibodies against EEA1 (B and
D), EGFR (F and H), or Rab5 (J), followed
by detection with secondary antibodies
conjugated to Texas Red. The arrows in-
dicate vesicular structure clearly visible
in both panels (colocalized), whereas the
arrowhead marks the vesicular structure
visible in one but not the other panel (not
colocalized). Scale bar 5 10 mm.
FIG. 8. Gel filtration analysis of protein complexes containing Hrs and SNX1. HeLa cell extracts were prepared as described under
“Experimental Procedures” and fractionated by size-exclusion chromatography using a Superose 6 high resolution analytical gel filtration column.
Equal volumes of each fraction were analyzed by SDS-PAGE, followed by immunoblotting for SNX1, Hrs, and EGFR. Standards used for column
calibration are blue dextran (2000 kDa), thyroglobulin (670 kDa), apoferritin (443 kDa), b-amylase (200 kDa), alcohol dehydrogenase (150 kDa),
albumin (66 kDa), and carbonic anhydrase (29 kDa).
Hrs Binds SNX1 and Regulates Lysosomal Trafficking7076
DISCUSSION
Trafficking of EGFR from endosome to lysosome plays a key
role in attenuating EGF signaling. However, little is known at
the molecular level about the mechanisms that regulate the
lysosomal trafficking pathway. Previous studies have defined
the lysosome-targeting signals within the cytoplasmic domain
of EGFR that are responsible for the EGF-induced lysosomal
degradation (42, 43). The first sorting nexin, SNX1, which
recognizes the EGFR lysosome-targeting signals, has recently
been identified and shown to function in lysosomal trafficking
of EGFR (14). In this paper, we describe a novel interaction
between SNX1 and Hrs, a protein that is implicated in both
vesicular trafficking and cell growth signaling. The interaction
of SNX1 with Hrs was demonstrated in the yeast two-hybrid
system and confirmed by in vitro binding studies and coimmu-
noprecipitation experiments. Deletion analysis reveals that the
Hrs-SNX1 interaction involves multiple coiled-coil domains
and complex folded structures of the Hrs central region (resi-
dues 225–541) and of the SNX1 COOH-terminal region (resi-
dues 300–522). Several lines of evidence support a physiologi-
cal significance of the observed interaction between SNX1 and
Hrs. 1) Hrs and SNX1 are ubiquitously expressed proteins that
exist in both cytosolic and membrane-associated pools. 2) Co-
immunoprecipitation experiments demonstrate that the asso-
ciation of Hrs and SNX occurs on cellular membranes but not in
the cytosol. 3) Gel filtration analysis reveals the presence of an
endogenous ;550-kDa protein complex containing SNX1 and
Hrs. 4) Subcellular fractionation studies show that SNX1 co-
fractionates with Hrs and early endosomal markers on an
Optiprep density gradient. 5) Double immunofluorescence
analysis demonstrates that Hrs and SNX1 colocalize on early
endosomes. 6) Overexpression of Hrs or its SNX1-binding do-
main inhibits ligand-induced degradation of EGFR, but has no
effect on EGFR internalization. Together, these data suggest
that the interaction between SNX1 and Hrs may be involved in
the regulation of endosome-to-lysosome trafficking of EGFR.
Our results indicate that SNX1 and Hrs share similar prop-
erties with their yeast homologues, Vps5p and Vps27p. In
yeast, both Vps5p and Vps27p are localized to the prevacuolar/
endosomal compartment, although it is not known whether
they colocalize with each other (17, 18, 44). In mammalian
cells, we found that Hrs and SNX1 colocalize on the early
endosome, a sorting compartment where membrane proteins
destined for degradation are sorted away from proteins that are
recycled back to cell surface. The involvement of SNX1 and Hrs
in lysosomal trafficking of EGFR is consistent with the role of
Vps5p and Vps27p in yeast vesicular trafficking. Recently, it
was reported that Vps5p assembles with Vps17p, Vps26p,
Vps29p, and Vps35p to form a novel coat complex called the
retromer complex (18). The presence of mammalian homo-
logues of other retromer components Vps26p, Vps29p and
Vps35p suggest that SNX1 may function in a manner that is
analogous to Vps5p by forming a retromer-like coat complex in
mammalian cells (18). Since SNX1 directly interacts with lyso-
some-targeting signals on cargo proteins such as EGFR (14), it
is likely that SNX1 performs its sorting function by selectively
recruiting specific cargo proteins into the retromer-like coat
complex.
The mutually exclusive interaction of Hrs and of EGFR with
SNX1 indicates that the association of Hrs with SNX1 is likely
to interfere with the ability of SNX1 to bind and recruit EGFR
into a functional coat complex for delivery to lysosomes. Sup-
porting this view, overexpression of Hrs or its SNX1-binding
domain in HeLa cells leads to an inhibition of lysosomal traf-
ficking of EGFR for degradation. Based upon these data, a
model for the role of Hrs in lysosomal trafficking can be envis-
aged. Hrs, by interacting with SNX1, might serve as a regula-
tor for the assembly of functional sorting machinery. The as-
sociation of Hrs with SNX1 keeps SNX1 in an inactive state,
FIG. 9. Coimmunoprecipitation analyses reveal the presence
of the HrszSNX1 and SNX1zEGFR complexes but not the
HrszSNX1zEGFR complexes. Extracts from HeLa cells transiently
transfected with pAlterMAX-EGFR alone (lanes 5 and 6) or in combi-
nation with pCHA-SNX1 (lanes 1 and 2) or pCHA-Hrs (lanes 3 and 4)
were subjected to immunoprecipitation (IP) with anti-HA antibody
3F10 (lanes 1 and 3), anti-EGFR antibody 528 (lane 5) or corresponding
control IgG (lanes 2, 4, and 6). The immunoprecipitates were analyzed
by immunoblotting (IB) with anti-EGFR, anti-Hrs, or anti-SNX1
antibodies.
FIG. 10. Effect of overexpression of SNX1, Hrs, and Hrs225–776
on degradation of EGFR. HeLa cells were transiently transfected
with pAlterMAX-EGFR in combination with pCHA vector control
(Cont.), pCHA-Hrs (Hrs), pCHA-Hrs225–776 (HrsDN), or pCHA-SNX1
(SNX1). At 24 h after transfection, cells were subjected to serum star-
vation, followed by incubation in the absence or presence of 100 ng/ml
EGF for 45 min at 37 °C. Cells were then lysed, and equal amounts (600
mg) of protein from each lysate were immunoprecipitated (IP) using
anti-EGFR antibody 528. The immunoprecipitates were analyzed by
immunoblotting (IB) with anti-EGFR antibody 1005 (A), and the corre-
sponding lysates (50 mg of protein/lane) were sequentially immuno-
blotted with anti-HA antibody (B) and anti-actin antibody (C). The
remaining EGF receptor level after stimulation with EGF for 45 min
was measured by quantification of the intensity of the 180-kDa EGFR
band, and expressed as a percentage of the EGFR level of unstimulated
cells that were identically transfected (D). Data are mean 6 S.E. (error
bar) of the results from four independent experiments.
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unavailable to interact with cargo proteins and/or with other
components of the retromer-like coat complex. Disruption of
this association by protein phosphorylation (6, 7) or interaction
with signaling proteins such as STAM and STAM2/Hbp (7, 10,
11) would then increase the availability of SNX1 and promote
cargo recruitment and assembly of functional coat complexes,
and hence facilitate lysosomal sorting and trafficking. Future
studies will test this model and determine the molecular mech-
anisms by which Hrs and SNX1 regulate vesicular trafficking.
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